tbuckley/cabot-search huggingface dataset:
Does Skipping Breakfast Lead to Weight Loss or Weight Gain?
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Balint groups: psychosocial nonsense or a real insight into the doctor-patient relationship?
Authors: Bruno Rushforth, Wendy Brown
Journal: BMJ (2004)

We have all come across them, but how should we react? That patient who keeps returning to their family doctor, with volumes of notes, numerous letters from specialists, but no disease is ever found. Or the patient who has not visited the doctor for 20 years and then presents with depression but says he or she does not want to talk about it. And then there is the patient who keeps bringing you gifts. This is where psychosocial medicine comes in. Love it or hate it—you cannot ignore it.

Around the world, medical training is increasingly demanding an understanding of patients' problems that goes beyond the organic nature of disease. Some students resent having to study these “soft” behavioural and social sciences, which take them away from the “real” medicine of anatomy, physiology, and pharmacology. Yet to ignore the powerful influence of health beliefs and emotions is to deny the psychosomatic dimension of many patients' presentations.

A key element is how the doctor responds in the consultation room. Indeed, the doctor-patient relationship itself can be a powerful therapeutic tool. But it is also important to acknowledge how some patients make us feel. Understanding our own emotional responses to difficult consultations can sometimes shed light on the patient's underlying problems.



JUST ART/BRIAN JAKOB/PHOTONICA



To explore these issues in the doctor-patient relationship we attended a weekend in Oxford, organised by the Balint Society. Who are they? Good question-until the advert appeared in the Student BMJ we had not heard of them either.

The UK Balint Society is part of an international federation of …
Understanding personality type: How do you like to take in information? Sensing and intuition
Authors: Anita Houghton
Journal: BMJ (2004)

In the third article of her series, Anita Houghton explains the two different ways in which people take in information and how both kinds of information processing can complement each other

Some years ago I did an MSc, and the course was taught by a variety of lecturers, two of whom stick out in my memory. The reason I remember these two in particular is that they divided the group so sharply into those that liked one and those that liked the other. The first of these, let's call him David, lectured us on the subject of health economics, and his lectures would start with a title and then take that theme excitedly from one topic to another, pulling in one theory here, another theory there, and ending up with, well, a group of theories, and a group of facts, and some haphazard links between the two. At the end of these lectures, most us would have a piece of paper with the title at the top, a half written sentence, and absolutely nothing else. The other lecturer, Susan, taught medical sociology. She would take a subject, and then deliver a perfect list of what we needed to know. At the end of these lectures we would have an excellent set of notes, easy to read, easy to learn, and easy to reproduce.

One group of students loved David's lectures. They were slightly disappointed to have buy books to supplement them, but that was easily offset by the sheer exhilaration of hearing him talk, the boundless theories, the different ways of looking at them, and the endless potential for new ideas and possibilities. The other group were bewildered and exasperated by …
Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death
Authors: Pradeep Natarajan, Tim S. Collier, Zhicheng Jin, Asya Lyass, Yiwei Li, Nasrien E. Ibrahim, Renata Mukai, Cian P. McCarthy, Joseph M. Massaro, Ralph B. D’Agostino, Hanna K. Gaggin, Cory Bystrom, Marc S. Penn, James L. Januzzi
Journal: Journal of the American College of Cardiology (2019)
Deriving Real-World Insights From Real-World Data
Authors: Stuart G. Baker
Journal: Annals of Internal Medicine (2019)

Letters7 May 2019Deriving Real-World Insights From Real-World DataStuart G. Baker, ScDStuart G. Baker, ScDNational Cancer Institute, Bethesda, Maryland (S.G.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0084 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In reviewing promising approaches to derive real-world insights from real-world data, Pencina and colleagues (1) discuss comparative research methods that mimic randomized trials. One method that the authors did not mention but that clinical researchers should have in their toolkit is the paired availability design (2–5), a way to design and analyze multiple before-and-after studies over a short time.The design aspect involves 2 steps. Investigators first collect outcome data at medical centers in the before period when a new treatment has limited or no availability. They then increase the availability of the new treatment in these ...References1. Pencina MJ, Rockhold FW, D'Agostino RB. Deriving real-world insights from real-world data: biostatistics to the rescue. Ann Intern Med. 2018;169:401-2. [PMID: 30039173]. doi:10.7326/M18-1093 LinkGoogle Scholar2. Baker SG, Lindeman KS. The paired availability design: a proposal for evaluating epidural analgesia during labor. Stat Med. 1994;13:2269-78. [PMID: 7846425] CrossrefMedlineGoogle Scholar3. Baker SG, Lindeman KS, Kramer BS. The paired availability design for historical controls. BMC Med Res Methodol. 2001;1:9. [PMID: 11602018] CrossrefMedlineGoogle Scholar4. Baker SG, Lindeman KL. Revisiting a discrepant result: a propensity score analysis, the paired availability design for historical controls, and a meta-analysis of randomized trials. J Causal Inference. 2013;1:51-82. CrossrefGoogle Scholar5. Baker SG, Kramer BS, Lindeman KS. Latent class instrumental variables: a clinical and biostatistical perspective. Stat Med. 2016;35:147-60. [PMID: 26239275] doi:10.1002/sim.6612 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: National Cancer Institute, Bethesda, Maryland (S.G.B.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0084. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDeriving Real-World Insights From Real-World Data: Biostatistics to the Rescue Michael J. Pencina , Frank W. Rockhold , and Ralph B. D'Agostino Sr. Metrics 7 May 2019Volume 170, Issue 9Page: 664-665KeywordsAnalgesiaConflicts of interestDisclosureObservational studiesRandomized trials ePublished: 7 May 2019 Issue Published: 7 May 2019 PDF downloadLoading ...
The World I Made for Her
Authors: Emma Wells
Journal: BMJ (2001)

James Bletchley has been in intensive care in a New York hospital for 50 days. When awake, he is an acute observer of his clinical surroundings. He watches the arrivals, ailments, and departures of other patients, his own drug regimen, and the various machines he relies on for breath and nutrition. He hears the medical opinions spoken softly or laced with jargon and he learns the intimate details of …
Reducing the stigma of mental illness
Authors: Jim Bolton
Journal: BMJ (2003)

The days of telling your patients to “pull themselves together” should be over. Jim Bolton discusses the various ways in which health professionals can help to reduce the stigma of mental illness at a professional, service, and individual level

Mental health problems are treated as if our thoughts and feelings are separate from our physical bodies. This artificial distinction is reflected in our thinking and language as well as in the provision of health services.

This separation of mind and body contributes to the stigma of mental illness. The description of mental health problems as being “all in the mind” is often followed by the instruction to the patient to “pull yourself together.” As a liaison psychiatrist who works in the divide between mental and physical health services, I have many reasons to consider the stigma of mental illness and how it should be tackled.

The artificial divide between physical and mental health services is shown by the high rates of psychological morbidity in general hospitals. Medical and surgical patients have higher rates of anxiety and depression than patients in the wider community, and one third of adult male inpatients drink alcohol in amounts that are hazardous to their health.1 Up to 5% of patients presenting at emergency departments have primary psychiatric problems.2

Having separated the organisation, location, and funding of mental and physical health services in the United Kingdom, we are now struggling to bring them together to meet the psychological needs of general hospital patients. This need is met by liaison psychiatry, which provides psychological care for such patients.3 It also provides important opportunities for combating the stigma of mental illness.

Stigma marks an individual out as being different and evokes some form of sanction. Illnesses can often be the stigmatising characteristic. However, whereas the …
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes
Authors: Bart G.J. Dekkers, Mathieu S. Bolhuis, Lies ter Beek, Wiel C.M. de Lange, Tjip S. van der Werf, Jan-Willem C. Alffenaar, Onno W. Akkerman
Journal: European Respiratory Journal (2019)

<b>Exposure to moxifloxacin is low in patients with tuberculosis and diabetes comorbidity due to increased clearance of the drug. As low exposure may result in poor treatment outcomes, higher moxifloxacin doses may be required for treatment success.</b>http://bit.ly/2Ynxdf7
I have crossed over to the other side
Authors: Libby Wilkinson
Journal: BMJ (2001)

Before I started medicine, I had always thought that nurses and doctors were a similar species. After all, don't we want the same things-the patients to get better, job satisfaction, and regular coffee breaks? Now I have “crossed over to the other side” I am much more aware of how different the two professions are.

I decided to go into nursing after doing A levels in English literature, history, and politics and being sure that I did not want to spend the next three years dissecting the finer points of Shakespeare. In fact, ever since, I have not read a “proper” book and still dislike broadsheet newspapers.

Nurse training was an interesting but at times frustrating experience. We were guinea pigs for the now obsolete Project 2000 course that was set up with the aim of making the nursing profession more academic. The idea was essentially good- training nurses with a greater theoretical basis on which …
Escribiendo para Student BMJ lorsque votre premier langue ist nicht Englisch
Authors: Jasmin Arrich, Adrián González Aguirre
Journal: BMJ (2003)

<b>Student BMJ</b> is read and written by international medical students. But writing in a language that may not be your first is understandably difficult. Here, two of our non-native English speaking student advisers, Jasmin Arrich and Adrián González Aguirre, give some advice on how they do it and persuade you that it is possible
LRP130: A possible effector of the mTOR-mediated mRNA translation
Authors: Katsuhiko Nakashima, Naoto Tsuchiya, Takashi Sugimura, Hitoshi Nakagama
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

4512 

LRP130, also known as LRPPRC, was first identified as a highly expressed transcript in a hepatocellular carcinoma cell line, HepG2. Subsequently, it has been revealed to be over-expressed in various other types of human cancer cell lines as well (our unpublished data). Over-expression of LRP130, therefore, could play some beneficial role in tumor cell growth, however, the details of biological functions still remain unsolved. We recently demonstrated LRP130 to be a novel type of RNA-binding protein, mainly localized in the cytoplasm especially in the outer nuclear and endoplasmic reticulum membranes, which interacts with mRNA/mRNP complexes at these sites. To further clarify the biological role of LRP130, interacting proteins in culture cells were immunoprecipitated with an anti-LRP130 antibody and their amino acid sequences were partially determined by LC/MS/MS analyses. Interestingly, an RNA-binding protein, hnPNP K, was showed to interact with LRP130 in an RNA-dependent manner. A considerable number of other RNA-binding proteins were also co-precipitated as candidate partners. Since one of the major functions of hnRNP K in the cytoplasm is its involvement in stability and translation of a subset of mRNA species, we attempted to clarify whether LRP130 could also be involved in translational regulation of some specific mRNA species in vivo. The cytoplasmic LRP130 in HeLa cells was co-fractionated with polysomes using sucrose gradient sedimentation. This co-localization was substantially inhibited by treatment of the cells with an mTOR kinase inhibitor, rapamycin, which is well known to repress the 5’ Cap-dependent mRNA translation. In contrast, the amount of LRP130 in polysome fractions was markedly increased by treatment of the HeLa cells with insulin, a potent stimulator of the mTOR signaling pathway. About 60 mRNA species, including those encoding cell cycle regulators and cell motility and chromatin maintenance proteins, have been identified thus far as binding to LRP130 in vivo using RNP immunoprecipitation (RIP) and subsequent GeneChip® (Affymetrix) analyses. Our results strongly suggest that LRP130 could serve as a downstream effector of the mTOR signaling pathway and thereby modulate mRNA translation activated by various growth factors and oncogenic stimuli.
Medics worldwide: news from the IFMSA
Authors: Emily Spry
Journal: BMJ (2004)

Last month saw an important meeting of African medical student leaders hosted by students from Obafemi Awolowo University in Nigeria. The theme of the meeting was “Consolidating our efforts for a better African medical student movement.” Participants considered the major challenges that African medical student organisations face in their work to represent, educate, and empower their peers. Plans are now under way for a congress to bring together medical student representatives of all African countries in December 2004. To lend your support to the first ever large scale IFMSA meeting for Africa, contact Jo (email rcafrica@ifmsa.org).

The Bologna process …
Teaching High-Value Care Through Conscious Ordering of Diagnostic Tests—Reply
Authors: Joshua D. Geleris, George Shih, Lia S. Logio
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation
Authors: Ceren Duman, Kaneschka Yaqubi, Angelika Hoffmann, Azer Aylin Acikgöz, Andrey Korshunov, Martin Bendszus, Christel Herold-Mende, Hai-Kun Liu, Julieta Alfonso
Journal: Cell Metabolism (2019)
What's on the web: The Olympics
Authors: Klaus Morales, Tulio Campos
Journal: BMJ (2004)

In 1896, Athens hosted the first modern version of the Olympic Games. This year, history repeats itself and the games are in Athens again. Much has changed: scientific advances in sports medicine have enabled athletes to improve their physical strength and perfect their technique.



CREDIT



The American Medical Society for Sports Medicine (www.amssm.org provides insight into the life of a sports doctor. The site also showcases opportunities for work, including fellowships …
Doctors on the frontline
Authors: Balaji Ravichandran
Journal: BMJ (2006)

Medecins Sans Frontieres (MSF) has never shied away from integrating aid efforts with criticisms of authorities involved in war related human tragedies. It was thrown out of Ethiopia in 1985 for whistleblowing on the misuse of aid and more recently in Rwanda for savaging the government on the state of the prisons. Last year, it asked its donors to stop sending money for the victims of the Indian Ocean tsunami, as it claimed to have collected the necessary funds to manage the situation effectively.

MSF is a maverick among the aid agencies around the world, operating well away from the media glare to deliver medical aid in war torn areas and regions plagued by natural disasters. With an annual budget of $400m (£230m; 330m), MSF operates in more than 70 countries, providing medical care in acute crises and raising international awareness of potential humanitarian disasters.

In a four part series, television cameras follow MSF's medical staff for the first time, in Haiti, Sudan, Honduras, and Somalia, to provide a direct account of their extraordinary service to humanity.

The programme, narrated by Scottish singer Annie Lennox, …
Gonorrhoea in England on the increase
Authors: Siân Knight
Journal: BMJ (2000)

The incidence of gonorrhoea in England rose steeply between 1998 and 1999, according to initial figures released last month by the Public Health Laboratory Service (PHLS). Reported diagnoses of the disease increased by 26% in men and by 30% in women, although a much bigger increase occurred in the group aged 16-19 years, which showed a rise of 52% in young …
Aspirin Use and the Risk of Cancer
Authors: Marko Skelin, Eugen Javor, Marko Lucijanic
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck
Authors: A. A. Meluch, D. Spigel, H. A. Burris, C. Lane, J. D. Peyton, D. Shipley, M. Rubin, M. Stipanov, F. A. Greco, J. D. Hainsworth
Journal: Journal of Clinical Oncology (2009)

6012 Background: Concurrent chemotherapy/RT is the standard of treatment for locally advanced head and neck cancer. Agents targeting EGFR and the angiogenesis pathway have also demonstrated activity. In this phase II trial, we added bevacizumab and erlotinib to an active combined modality regimen in the first-line treatment of pts with locally advanced head and neck cancer. Methods: Eligible pts had previously untreated squamous carcinoma of any head and neck site, with T3/T4 primary lesions and/or N1-N3 nodal involvement. Additional eligibility: ECOG PS 0 or 1; adequate organ function; indwelling central venous catheter; standard bevacizumab exclusions. All pts received induction therapy with 2 courses of paclitaxel (200mg/m 2 ), carboplatin (AUC 6.0), 5-FU (200mg/m 2 per day, 24 hour CI days 1–21), and bevacizumab (15 mg/kg); cycles were repeated at 21-day intervals. Pts then received concurrent RT (68.4 Gy, 1.8 Gy/day), paclitaxel (50 mg/m 2 weekly x 6), bevacizumab (15 mg/kg weeks 1 and 4), and erlotinib (150 mg daily x 7 weeks). PFS was the primary endpoint. Results: Between December 2006 and July 2008, 60 pts were enrolled; the first 48 pts are included in this preliminary report. The median age was 56 years; T3/T4 = 9/8; N1/N2/N3 = 13/27/4. 45 pts (94%) completed the 6-week induction therapy, and 41 pts (85%) completed all therapy. After induction therapy, 56% of pts had objective response; 77% had objective response after completion of therapy. After a median follow-up of 16 months, the 18-month progression-free and overall survivals are 85% and 87%, respectively. Grade 3/4 toxicity during induction therapy included neutropenia (46%), neutropenic fever (6%), mucositis (14%), diarrhea (14%), and hand/foot syndrome (11%). Severe local toxicity (mucositis/esophagitis) occurred in 31 patients (76%) during combined modality therapy (56% grade 3/20% grade 4). Conclusions: The addition of bevacizumab and erlotinib to concurrent chemotherapy/RT was feasible, with no unexpected toxicity. After short followup, the regimen appears highly active. Updated results will be presented. [Table: see text]